Advertisement
COO vs RMD
Which Stock Would AI Choose? The Cooper Companies, Inc. (COO) vs. ResMed Inc. (RMD) Stock Comparison
Key Takeaways
- Both companies operate in the medical instruments and supplies industry, with COO focusing on vision care products and women's health solutions, while RMD specializes in sleep apnea and respiratory devices.
- RMD boasts a larger market capitalization ($32.3B vs. $12.6B) and superior profitability metrics, including ROE (return on equity) of 25.7% compared to COO's 4.9%.
- Recent market activity shows both stocks under pressure, with COO declining about 7% over the past month and 21% YTD, outpacing RMD's milder 1% monthly and 8% YTD drops.
- Analyst consensus targets imply significant upside: around 41% for COO ($91 average) and 31% for RMD ($290 average).
- Upcoming quarterly earnings could drive sentiment shifts for both, amid broader healthcare sector volatility.
Introduction
In the competitive medical devices sector, COO and RMD stand out as key players addressing distinct yet overlapping health needs. This comparison analyzes their recent stock performance, financial health, and market positioning amid economic uncertainties and sector-specific trends like rising demand for at-home care. Investors seeking diversified exposure to healthcare innovation or traders eyeing short-term momentum will find value in understanding their relative strengths, valuation trade-offs, and potential catalysts in the current environment.
COO Overview and Recent Performance
The Cooper Companies, Inc. (COO) designs and manufactures vision care products like contact lenses and surgical devices for women's health. Trading at approximately $64 with a $12.6B market cap, the stock has faced downward pressure in recent weeks, sliding amid broader market volatility despite a Q1 fiscal 2026 earnings beat (EPS $1.10 vs. $1.03 expected). Year-to-date, shares are down over 21%, underperforming the sector, influenced by valuation concerns and slower revenue growth (6.2% quarterly YoY). Positive developments include new product launches like MyDay contact lenses and partnerships boosting brand visibility, potentially supporting sentiment recovery ahead of Q2 results.
RMD Overview and Recent Performance
ResMed Inc. (RMD) leads in sleep and respiratory solutions, including CPAP machines and digital health platforms. At around $222 and a $32.3B market cap, shares have shown relative resilience, down 1% over the past month and 8% YTD, buoyed by strong fundamentals like 11% quarterly revenue growth and robust ROE. Recent weeks reflect some weakness tied to post-earnings digestion, but analyst optimism persists with upcoming Q3 results on April 30 expected to show EPS growth. Demand for out-of-hospital care amid aging demographics continues to underpin performance, though beta of 0.93 indicates moderate market sensitivity.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from over 351 total bots that trade thousands of tickers across diverse strategies, timeframes, and market conditions. Only 25 bots earn a spot in this dynamic section based on real-time suitability and historical edge in current environments, featuring signal agents, virtual agents, and brokerage-linked options for copy trading. These bots vary in win rates, profit factors, trade frequencies, and focus sectors, helping users align with prevailing trends without manual analysis. Explore them to enhance your strategy today.
Head-to-Head Comparison
COO and RMD share sector exposure but diverge in business models: COO's consumer-driven vision products contrast RMD's emphasis on chronic disease management tech. Growth drivers include COO's innovation in daily disposables and RMD's software ecosystem expansion. Recent momentum favors neither decisively, with COO more volatile (beta 1.07) and lower P/E (forward 14.3 vs. 18.6), but RMD exhibits stronger balance sheet (current ratio 3.1 vs. 1.3, lower debt/equity). Risks encompass reimbursement changes and competition; sentiment tilts toward RMD's stability versus COO's rebound potential.
Tickeron AI Verdict
Tickeron's AI models lean toward RMD in the current landscape, citing superior trend consistency via better Smart Momentum Rating, higher ROE, and lower leverage amid recent stability. COO offers value post-slide with EPS growth, but probabilistic edges favor RMD's catalysts like earnings momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a Hold and RMD is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COO’s FA Score shows that 1 FA rating(s) are green whileRMD’s FA Score has 1 green FA rating(s).
- COO’s FA Score: 1 green, 4 red.
- RMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COO’s TA Score shows that 5 TA indicator(s) are bullish while RMD’s TA Score has 5 bullish TA indicator(s).
- COO’s TA Score: 5 bullish, 4 bearish.
- RMD’s TA Score: 5 bullish, 3 bearish.
Price Growth
COO (@Pharmaceuticals: Other) experienced а -3.45% price change this week, while RMD (@Pharmaceuticals: Other) price change was -2.23% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.31%. For the same industry, the average monthly price growth was -0.98%, and the average quarterly price growth was -14.76%.
Reported Earning Dates
COO is expected to report earnings on Sep 02, 2026.
RMD is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.31% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| COO | RMD | COO / RMD | |
| Capitalization | 12.8B | 27.3B | 47% |
| EBITDA | 1.08B | 2.18B | 50% |
| Gain YTD | -20.181 | -21.348 | 95% |
| P/E Ratio | 55.44 | 18.17 | 305% |
| Revenue | 4.15B | 5.54B | 75% |
| Total Cash | 125M | 1.66B | 8% |
| Total Debt | 2.5B | 843M | 297% |
COO | RMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 86 | 38 | |
PRICE GROWTH RATING 1..100 | 59 | 64 | |
P/E GROWTH RATING 1..100 | 14 | 85 | |
SEASONALITY SCORE 1..100 | 46 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RMD's Valuation (15) in the Medical Specialties industry is somewhat better than the same rating for COO (72). This means that RMD’s stock grew somewhat faster than COO’s over the last 12 months.
RMD's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as COO (100). This means that RMD’s stock grew similarly to COO’s over the last 12 months.
RMD's SMR Rating (38) in the Medical Specialties industry is somewhat better than the same rating for COO (86). This means that RMD’s stock grew somewhat faster than COO’s over the last 12 months.
COO's Price Growth Rating (59) in the Medical Specialties industry is in the same range as RMD (64). This means that COO’s stock grew similarly to RMD’s over the last 12 months.
COO's P/E Growth Rating (14) in the Medical Specialties industry is significantly better than the same rating for RMD (85). This means that COO’s stock grew significantly faster than RMD’s over the last 12 months.
| COO | RMD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 60% | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 55% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 62% |
| MACD ODDS (%) | N/A | 2 days ago 59% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 49% | 2 days ago 59% |
| Advances ODDS (%) | 19 days ago 57% | 19 days ago 59% |
| Declines ODDS (%) | 8 days ago 60% | 13 days ago 59% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 72% |
| Aroon ODDS (%) | 2 days ago 50% | 2 days ago 61% |
Advertisement
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.
RMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, RMD has been loosely correlated with SOLV. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then SOLV could also see price increases.
| Ticker / NAME | Correlation To RMD | 1D Price Change % | ||
|---|---|---|---|---|
| RMD | 100% | -0.10% | ||
| SOLV - RMD | 46% Loosely correlated | -2.48% | ||
| COO - RMD | 46% Loosely correlated | -0.74% | ||
| BAX - RMD | 44% Loosely correlated | -1.16% | ||
| NVST - RMD | 41% Loosely correlated | -1.54% | ||
| RVTY - RMD | 40% Loosely correlated | -0.96% | ||
More | ||||